Wealth Enhancement Advisory Services
ANIK icon

Wealth Enhancement Advisory Services’s Anika Therapeutics ANIK Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
15,577
+5,531
+55% +$82K ﹤0.01% 3409
2026
Q1 		$149K Buy
+10,046
New +$117K ﹤0.01% 3230

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Wealth Enhancement Advisory Services's ANIK Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Anika Therapeutics (ANIK) stake by 55% in Q2 2026, buying an estimated $82K and bringing the position to 15,577 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

Wealth Enhancement Advisory Services first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Wealth Enhancement Advisory Services held 15,577 shares of Anika Therapeutics worth $243K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 5,531 Anika Therapeutics shares in Q2 2026, an estimated $82K.
  • Anika Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3409 holding.
  • Wealth Enhancement Advisory Services first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.